Journal
LEUKEMIA & LYMPHOMA
Volume 63, Issue 13, Pages 3052-3062Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2022.2113526
Keywords
Large B-cell lymphoma; axicabtagene ciloleucel; lisocabtagene maraleucel; CAR T-cell therapy; MAIC; comparative efficacy
Categories
Funding
- Kite, A Gilead Company
Ask authors/readers for more resources
An unanchored matching-adjusted indirect comparison was used to estimate the relative treatment effects of Axi-cel and liso-cel for relapsed/refractory large B-cell lymphoma. The results suggest that Axi-cel improved survival compared to liso-cel, but with increased odds of specific adverse events.
In the absence of a randomized head-to-head trial, an unanchored matching-adjusted indirect comparison was performed to estimate the relative treatment effects of axicabtagene ciloleucel (axi-cel; ZUMA-1) versus lisocabtagene maraleucel (liso-cel; TRANSCEND-NHL-001) for treatment of relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after at least two lines of therapy. After matching, axi-cel and liso-cel had comparable objective response rates and duration. Compared to liso-cel, axi-cel was associated with improvements in overall survival (hazard ratio [HR]: 0.53 [95% CI: 0.34-0.82]) and progression-free survival (HR: 0.61 [95% CI: 0.40-0.92]). Axi-cel was associated with a higher rate of grade >= 3 cytokine release syndrome (odds ratio [OR]: 3.64 [95% CI: 1.04-12.76]) and neurological events (OR: 3.45 [95% CI: 1.65-7.19]), with smaller differences estimated in scenario analyses including ZUMA-1 safety management cohorts. Results suggest axi-cel improved survival compared to liso-cel but with increased odds of specific adverse events.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available